SPRAVATO® is the first prescription nasal spray (taken in conjunction with an oral antidepressant) specifically for adults with treatment-resistant depression.
What is treatment-resistant depression?
Treatment-resistant depression is diagnosed in adults who were struggling with major depressive disorder and had not responded adequately to at least two different antidepressants of adequate dose and duration in the current depressive episode.
Treatment with SPRAVATO®
SPRAVATO® is taken along with an oral antidepressant. You will administer SPRAVATO® nasal spray yourself under the supervision of a provider at Redefine Healthcare. SPRAVATO® sessions are twice a week for the first four weeks, and then once a week after the first four weeks. After this, SPRAVATO® is usually taken either once a week or once every two weeks, but can vary depending on the response.
How is SPRAVATO® different from other antidepressants?
Today’s most commonly used oral antidepressants are thought to treat depression by increasing levels of neurotransmitters (serotonin, norepinephrine and dopamine) in areas of the brain that affect mood. SPRAVATO® works differently in that it targets the N-methyl-D-aspartate (NMDA) receptor and is believed to work differently than currently available oral antidepressants.
Is SPRAVATO® right for you?
If you’ve struggled with depression and tried two or more antidepressants in your current episode without adequate relief, talk to your provider at Redefine Healthcare to see if SPRAVATO® may be an option for you.
Redefine Healthcare will begin offering SPRAVATO® treatment in our Edison and Union offices at the end of this month. Call (732) 906-9600 or go to RedefineHealthcare.com to schedule a consultation.
SPRAVATO® is not for use as a medicine to prevent or relieve pain (anesthetic). It is not known if SPRAVATO® is safe or effective as an anesthetic medicine.
It is not known if SPRAVATO® is safe and effective for use in preventing suicide or in reducing suicidal thoughts or actions. SPRAVATO® is not for use in place of hospitalization if your healthcare provider determines that hospitalization is needed, even if improvement is experienced after the first dose of SPRAVATO®. It is not known if SPRAVATO® is safe and effective in children.